Agoracom Blog Home

Archive for the ‘Featured’ Category

« Older Entries
Newer Entries »

Novamind $NM.ca $NVMDF to Present at Benzinga Conference $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 12:08 PM on Tuesday, February 23rd, 2021
  • Announced its participation in the Benzinga Cannabis Capital Conference, on February 25th and 26th, 2021, one of the select companies to be featured from the emerging psychedelics industry.
  • On Friday, February 26th, 2021 at 1:30pm EST, Novamind’s CEO and Director, Yaron Conforti, will present the Company’s vision for scaling access to psychedelic medicine and advancing clinical research.

TORONTO, ON / February 23, 2021 / Novamind Inc. (CSE:NM) (OTC PINK:NVMDF) (“Novamind” or “the Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Benzinga Cannabis Capital Conference (“the Conference”), on February 25th and 26th, 2021, one of the select companies to be featured from the emerging psychedelics industry.

On Friday, February 26th, 2021 at 1:30pm EST, Novamind’s CEO and Director, Yaron Conforti, will present the Company’s vision for scaling access to psychedelic medicine and advancing clinical research.

“We are excited to connect with investors who share our belief that innovative mental health therapies are disrupting the current standard of care in mental health,” said Yaron Conforti, CEO and Director of Novamind. “I look forward to this opportunity to share Novamind’s approach to mental healthcare and clinical research in psychedelic medicine.”

The Conference will also host a panel discussion on psychedelics with industry leaders including Novamind’s Chief Medical Officer, Dr. Reid Robison on Friday, February 26th, 2021 at 1:50pm EST.

For more information about the conference, please click here.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information:

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

Tags: , , ,
Posted in Featured, Novamind Inc. | Comments Off on Novamind $NM.ca $NVMDF to Present at Benzinga Conference $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

VIDEO – As Empower Clinics $CBDT.ca $EPWCF Makes New Highs On Multiple Major Announcements, CEO McAuley Discusses Why $100M Clinic Revenue Is Stage 1 – And Much More Is Coming $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 5:27 PM on Thursday, February 18th, 2021

When we conduct a “Beyond The Press Release” interview, it is always about A press release …. but Empower Clinics has been moving so fast that we sat down with CEO Steve McAuley to discuss these THREE press releases, the explosive growth of the Company and where it is going:

  • Partnership With Rexall To Launch Integrated Health Centres
  • Surpassed 1,000 COVID-19 tests on 1 day for first time ever … 3X Lab Expansion
  • Secured Medical Device Establishment License (MDEL) To Sell KAI Saliva

As usual, Six Sigma Steve McAuley doesn’t disappoint as he confidently and clearly tells investors where Empower Clinics is going next.

Tags: , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on VIDEO – As Empower Clinics $CBDT.ca $EPWCF Makes New Highs On Multiple Major Announcements, CEO McAuley Discusses Why $100M Clinic Revenue Is Stage 1 – And Much More Is Coming $WELL.ca $DOC.ca $DOCRF $VMD.ca

Universal PropTech $UPI Invests in and Secures defined Agency Rights for ISBRG Corp.’s SpotLight-19(C) Technology Designed to Detect Covid-19 Non-Invasively in Under One Minute $AAT.ca $LPS.ca $EGT.ca

Posted by AGORACOM-JC at 9:57 AM on Thursday, February 18th, 2021
  • ISBRG is a data analytics company which has developed the SpotLight technology platform designed to generate comprehensive health care data non-invasively within seconds at a nominal incremental cost per test.
  • SpotLight-19© is non-invasive, and ISBRG is undertaking trials to determine efficacy in detecting Covid-19.
  • In addition to its minority investment, UPI will act as the exclusive sales agent for the SpotLight-19© technology and other future platform offerings for the government and education sectors in Canada.

Toronto, Ontario–(February 18, 2021) – Universal PropTech Inc. (TSXV: UPI) (“UPI” or the “Company”) is pleased to announce that it has completed an investment in ISBRG Corp. (“ISBRG”) for a minority interest, and secured agency rights to their SpotLight-19© Technology.

ISBRG is a data analytics company which has developed the SpotLight technology platform designed to generate comprehensive health care data non-invasively within seconds at a nominal incremental cost per test. SpotLight-19© is non-invasive, and ISBRG is undertaking trials to determine efficacy in detecting Covid-19. In addition to its minority investment, UPI will act as the exclusive sales agent for the SpotLight-19© technology and other future platform offerings for the government and education sectors in Canada.

“We are proud and excited to be a strategic investor in ISBRG,” stated Chris Hazelton, President & CEO of Universal PropTech. “We have been committed to ensuring safe and healthy workspaces for our clients and facilitating the return of workers to workspaces in the face of the pandemic, and SpotLight-19© as a rapid, inexpensive and reusable testing platform to ensure safe work environments, could be a catalyst to opening global economies. Upon completion of trials and relevant governmental approvals, Universal PropTech expects that it will aggressively market SpotLight-19© products and supporting services to all governmental and education providers across Canada.”

“Our technology stems from the belief that technological innovation and strategic partnerships will restore economic growth globally in the midst of a pandemic that is challenging the speed, accuracy and effectiveness of existing tests” stated Duncan MacIntyre, Founder and CEO ISBRG.

ISBRG’s SpotLight-19© technology platform has proof of concept, and the funding now enables trials to determine the sensitivity and specificity of the device which will be compared to the accuracy of PCR tests in upcoming trials which are subject to authorization by Health Canada and REB review. Several published studies support ISBRG’s proof of concept and the application of light to detect viruses has been well documented in the past, see (https://pubmed.ncbi.nlm.nih.gov/29806030/).

The global Covid-19 diagnostics market size is estimated at USD$84.4 billion in 2020 and is expected to expand at a compounded annual growth rate (CAGR) of 3.1% from 2021 to 2027[1].

ISBRG headquartered in Mississauga, Ontario, developed its SpotLight-19© technology platform to monitor health – including a Covid-19 state of infection – using patent pending proprietary applications utilizing machine learning, optics and non-invasive interface design.

SpotLight-19© technology platform features:

  • a non-invasive scan of a person’s finger with a harmless beam of light
  • designed to provide confirmation of Covid-19 infection in less than 1 minute
  • low-cost testing.

ISBRG’s SpotLight-19© technology is intended for use in large venues, such as:

  • airports
  • border crossings
  • government buildings
  • schools and campuses
  • entertainment complexes, etc.

Should your organization wish to express an interest in procuring SpotLight-19©, please link and complete the Contact form. https://universalproptech.com/

ISBRG founder Duncan MacIntyre, is the former President of ICI in Canada and Latin America, the founding President of the National Quality Institute and co-author of more than 25 US patents in the field of spectroscopy. He has assembled a team of medical doctors, Ai specialists, hardware designers, internationally recognized optics experts and an ISBRG Board of Advisors that excel in their respective fields. The Board of Advisors includes:

  • former Global VP of AMGEN – Michael Kelly
  • former Canadian Astronaut and Author – Commander Chris Hadfield
  • former Director of Emera and Order of Canada appointee – Irene d’Entremont
  • former President of American Eagle Airlines – Peter Bowler
  • former Director General Global Operations CSIS – Allan MacDougall

Michael Kelly, former AMGEN Global VP, Thousand Oaks, California, states: “I became involved in ISBRG because of SpotLight-19©’s Ai and optical design innovations which, subject to confirmation in these trials, have the potential to significantly impact the global economic recovery more than any other technology available today”.

Read More: https://agoracom.com/ir/UniversalPropTech/forums/discussion/topics/755586-universal-proptech-inc-invests-in-and-secures-defined-agency-rights-for-isbrg-corp-s-spotlight-19-c-technology-designed-to-detect-covid-19/messages/2304191#message

Tags: , , , , , ,
Posted in Featured, Universal PropTech Inc. | Comments Off on Universal PropTech $UPI Invests in and Secures defined Agency Rights for ISBRG Corp.’s SpotLight-19(C) Technology Designed to Detect Covid-19 Non-Invasively in Under One Minute $AAT.ca $LPS.ca $EGT.ca

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Demonstrates Significant Scientific Capability by Validating its PCR Tests Accurately Detect COVID-19 U.K. and South Africa Variants $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:31 AM on Thursday, February 18th, 2021

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and travel industry

  • Announced KAI Medical Laboratory has validated that its various COVID-19 PCR test products are able to accurately detect the B.1.1.7 (UK variant) & B.1.351 (South African variant)

VANCOUVER BC / February 18, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce our KAI Medical Laboratory (“KAI LAB”) has validated that its various COVID-19 PCR test products are able to accurately detect the B.1.1.7 (UK variant) & B.1.351 (South African variant).

“The Kai Labs motto of Inspire by Science, Built on Integrity is displayed so accurately as the team of molecular scientists took it upon themselves to validate our test protocols against pervasive new COVID-19 variants.” said Steven McAuley, Chairman & CEO. “Leading with science, continuous improvement and a desire to impact healthcare outcomes elevates Kai Labs to a national and international stage. I expect this to be a competitive advantage as we endeavour to sign new global distribution and sales contracts.”

World Health Organization (WHO) Chief Scientist Confirms The U.K. Variant and South African Variants Are a Concern

Dr. Soumya Swaminathan comments “…scientists have now studied this and have found that these variants do tend to spread faster, they’re more transmissible or more infectious. So that’s the worrying part.”

KAI Medical Laboratory Research & Development a key differentiator for the Future

The KAI Lab testing protocol tests for parts of the viral genome that is not affected by the mutations in the spike protein the “S’ gene. In effect, this ensures the active virus in a patient’s RNA genetic sequence can be detected and a correct test result will be provided.

Dr. Soumya Swaminathan indicates “We know that testing, that identifying those who are infectious, that being able to provide them supportive isolation, tracking and contact tracing, and quarantining all the contacts…All of these things together definitely make a difference in bringing down transmission.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/755571-empower-clinics-kai-medical-laboratory-demonstrates-significant-scientific-capability-by-validating-its-pcr-tests-accurately-detect-covid-19-u-k/messages/2304168#message

Tags: , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Demonstrates Significant Scientific Capability by Validating its PCR Tests Accurately Detect COVID-19 U.K. and South Africa Variants $WELL.ca $DOC.ca $DOCRF $VMD.ca

VIDEO – Novamind $NM.ca Is Building the Infrastructure Required for a Regulated Psychedelics Industry $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 4:11 PM on Wednesday, February 17th, 2021

The global behavioural health market size is expected to reach approximately US$ 245 billion by 2027 and estimated to grow at CAGR of 2.5 % over the forecast time frame 2020 to 2027. 

As a consequence of the increasing incidence of mental health disorders, global demand for mental health facilities is increasing.

Psychedelics are going to go through parabolic, paradigm-shifting growth because of their ability to treat anxiety and depression amongst other things

Novamind is a leading mental health company specialized in psychedelic medicine, building the infrastructure required for a regulated psychedelics industry.

Highlights:

  • Rapidly expanding a network of outpatient mental health clinics and research sites
  • 4 clinics in Utah, 1 more anticipated this quarter
  • Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
    • Ketamine treatment volume grew 90% from 2019 to 2020
    • During the same period, total Spravato™ treatments rose 400%
  • Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
  • Building centers of excellence for future approved psychedelic treatments
  • Approximately CAN$1,900,000 in 2019 revenue
  • Strong insider ownership (32.3%)

Watch this powerful interview with Dr. Reid Robison, Chief Medical Officer and Director of Novamind.

Tags: , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Novamind Inc. | Comments Off on VIDEO – Novamind $NM.ca Is Building the Infrastructure Required for a Regulated Psychedelics Industry $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

CLIENT FEATURE: Novamind $NM.ca Leaders In #Psychedelic Medicine $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:44 AM on Friday, February 12th, 2021

NM: CSE

Why Novamind?

  • Building the infrastructure required for a regulated psychedelics industry
  • Rapidly expanding a network of outpatient mental health clinics and research sites
  • Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
    • Ketamine treatment volume grew 90% from 2019 to 2020
    • During the same period, total Spravato™ treatments rose 400%
  • Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
  • Specializing in psychedelic-assisted treatment protocols
  • Building centers of excellence for future approved psychedelic treatments
  • Approximately CAN$1,900,000 in 2019 revenue
  • Strong insider ownership (32.3%) 

Yaron Conforti, CEO of Novamind Featured On Cheddar News

Novamind is focused on 3 pillars:

FULL DISCLOSURE: Novamind is an advertising client of AGORA Internet Relations Corp.

Hub On AGORACOM / Corporate Profile

Tags: , , , , , , ,
Posted in AGORACOM Client Feature, All Recent Posts, Featured, Novamind Inc. | Comments Off on CLIENT FEATURE: Novamind $NM.ca Leaders In #Psychedelic Medicine $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

ThreeD Capital Inc. $IDK.ca $IDKFF Makes $300,000 Investment Into Carl Data Solutions Inc. $CRL.ca $IP.ca $IPNFF $PKK.ca $PKKFF $MTRX $RACMF

Posted by AGORACOM-JC at 10:42 AM on Friday, February 12th, 2021
IDK-square-for-blog
  • Announced a $300,000 investment in Carl Data Solutions Inc. (CSE: CRL) (OTCQB: CDTAF), an Industrial IoT (IIoT) and Big Data as a Service (BDaaS) company that provides next generation collection, storage, and analytics solutions for data-centric organizations
  • Sheldon Inwentash, Chairman and CEO of ThreeD Capital stated, “We are very impressed with the technology that Carl has developed that offers real world insights across industries in terms of capturing and analyzing meaningful data and providing predictive analytics, which organizations and cities can act upon. This has tremendous implication for the environment, cost-savings, and organizational and governmental efficiencies.

TORONTO, Feb. 12, 2021- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK) (OTCQB:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce a $300,000 investment in Carl Data Solutions Inc. (“Carl”) (CSE: CRL) (OTCQB: CDTAF), an Industrial IoT (IIoT) and Big Data as a Service (BDaaS) company that provides next generation collection, storage, and analytics solutions for data-centric organizations.

The Company has acquired 2,000,000 units (the “Units”) at a price of $0.15 per Unit for aggregate proceeds of $300,000. Each Unit consists of one (1) common share of Carl (a “Common Share”) and one Common Share purchase warrant (a “Warrant”), exercisable at a price of $0.25 per Warrant. The Warrants will expire two (2) years from the date of issuance.

Sheldon Inwentash, Chairman and CEO of ThreeD Capital stated, “We are very impressed with the technology that Carl has developed that offers real world insights across industries in terms of capturing and analyzing meaningful data and providing predictive analytics, which organizations and cities can act upon. This has tremendous implication for the environment, cost-savings, and organizational and governmental efficiencies.

Carl Data Solutions provides tools to model and predict the impact of environmental events. Using Carl’s cloud based core IT platform, Software as a Service (SaaS) applications, purpose built hardware arrays and custom data collection networks, Carl delivers end to end solutions for Industry and Government. Carl Data Solutions has invested millions of dollars into creating a technology that revolutionizes the way industries extract value from their data. Carl’s technology is now widely deployed by both Industry and Government to automate and organize data collection, storage and analysis. The demand for smart scalable solutions is growing rapidly with the explosion of new data from IoT devices. Carl is succeeding at answering the call for new ways to access and make sense of enormous amounts of data through Carl’s unique and disruptive technology.

Read More: https://agoracom.com/ir/threedcapital/forums/discussion/topics/755251-threed-capital-inc-makes-300-000-investment-into-carl-data-solutions-inc/messages/2303421#message

Tags: , , , , , , ,
Posted in Featured, ThreeD, ThreeD Capital | Comments Off on ThreeD Capital Inc. $IDK.ca $IDKFF Makes $300,000 Investment Into Carl Data Solutions Inc. $CRL.ca $IP.ca $IPNFF $PKK.ca $PKKFF $MTRX $RACMF

VIDEO – AGORACOM Beyond The Expert Welcomes Venture Capitalist Leigh Hughes To Discuss Mountain Valley MD $MVMD, Valeo Pharma $VPH $VPHIF and Xphyto Therapeutics $XPHY $XPHYF

Posted by AGORACOM-JC at 6:36 PM on Thursday, February 11th, 2021

AGORACOM followers have given us great feedback on our hit series “Beyond The Press Release” (BTPR) in which we speak with small cap CEO’s about important press releases in greater depth and, quite frankly, in layman’s terms for investors to truly understand their significance.  

Nowhere is this more important than in the world of disruptive technologies, biotech and pharma.  Each of these industries share two distinct traits:

  • The possibility for explosive growth with disruptive new products
  • Difficulty in conveying disruptive new products that, by their nature, have never been seen before by investors.

Whereas BTPR tells these stories from the side of small cap public companies, Beyond The Expert (BTE) tells these stories from the perspective of experts on these topics – and we couldn’t think of anyone better to start off this series than Leigh Hughes.  

Leigh is a Venture Capitalist who I’ve personally watched conduct incredible due diligence and invest into many small cap companies that have generated incredible returns over 12-18 month periods.    

Leigh is so good at what he does that many global private equity funds and institutions take his call and often follow him into investments he chooses to make.  Moreover, he serves as an advisor to several small cap companies.

If you ever wanted to truly learn how to become a great small cap investor, it doesn’t get much better than this.  

Without further adieu, watch this great interview with Leigh Hughes and make sure to provide us with your feedback via comments on Twitter, YouTube or wherever you may be watching or listening.

Tags: , , , , , , ,
Posted in AGORACOM Beyond The Expert, All Recent Posts, Featured, Mountain Valley MD, Valeo Pharma Inc, Xphyto Therapeutics | Comments Off on VIDEO – AGORACOM Beyond The Expert Welcomes Venture Capitalist Leigh Hughes To Discuss Mountain Valley MD $MVMD, Valeo Pharma $VPH $VPHIF and Xphyto Therapeutics $XPHY $XPHYF

Novamind $NM.ca Announces Strategic Investment in #Bionomics $BNOEF to Support #PTSD Clinical Trial $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:20 AM on Thursday, February 11th, 2021

Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment

  • Announced that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the “Strategic Investment”), in Bionomics Limited (“Bionomics”) (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
  • In addition, Cedar Clinical Research (“CCR”), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ Phase IIb trial examining BNC210.
  • BNC210 has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).

TORONTO, ON / February 11, 2021 / Novamind Inc. (CSE:NM) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the “Strategic Investment”), in Bionomics Limited (“Bionomics”) (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.

In addition, Cedar Clinical Research (“CCR”), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ Phase IIb trial examining BNC210. BNC210 has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).

With its investment in Bionomics, Novamind joins a group of well-known investors that specialize in psychedelics and biotech: Apeiron Investments, Biotech Value Fund, Merck & Co., Mike Novogratz, and Peter Thiel, an early investor in ATAI Life Sciences.

Novamind’s Strategic Investment is included in Bionomics’ latest round of financing, which was underwritten by Apeiron Investments and received commitments for AU$16,000,000 (approximately CAN$15,680,000, the “Bionomics Financing”). Novamind will purchase a total of 5,706,800 common shares in the Bionomics Financing, at AU$0.145 per share, a 20% discount to the 30-day volume weighted average price as of February 5th, 2021. Proceeds from the Bionomics Financing will support the initiation of a Phase IIb trial for BNC210, planned for mid-2021.

Bionomics intends to evaluate Cedar Clinical Research’s deep expertise in facilitating Phase I to Phase IV clinical trials for leading pharmaceutical companies, and how it may potentially serve as a research site for Bionomics’ Phase IIb clinical trial examining BNC210 in PTSD patients.

Cedar Clinical Research, led by Novamind’s Chief Medical Officer, Dr. Reid Robison, is currently contracted for seven clinical trials with various sponsors, including leading pharmaceutical companies. Dr. Robison has led over 100 clinical trials in neuropsychiatry, researching a spectrum of psychiatric conditions, including PTSD.

“I’m happy to welcome Novamind as a strategic investor in Bionomics,” said Dr. Errol De Souza, Executive Chairman of Bionomics. “Dr. Robison and the team at Cedar Clinical Research have unique experience related to clinical trials for mental health therapeutics.”

Yaron Conforti, CEO and Director of Novamind, added, “We are pleased to participate in Bionomics’ financing to support the development of its novel drug candidate for the treatment of PTSD. Cedar Clinical Research has unique expertise in PTSD research, and we look forward to the opportunity to contribute to the development of BNC210.”

To learn more about Cedar Clinical Research, please visit cedarclinicalresearch.com.

About Bionomics

Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in development for initiation of a second Phase II trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada). To learn more, please visit bionomics.com.au.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

Read More: https://agoracom.com/ir/Novamind/forums/discussion/topics/755165-novamind-announces-strategic-investment-in-bionomics-to-support-ptsd-clinical-trial/messages/2303206#message

Tags: , , , , , , , ,
Posted in Featured, Novamind Inc. | Comments Off on Novamind $NM.ca Announces Strategic Investment in #Bionomics $BNOEF to Support #PTSD Clinical Trial $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

VIDEO – PyroGenesis $PYR.ca Goes Live For Q&A With Shareholders As Market Cap Surpasses $1 BILLION

Posted by AGORACOM-JC at 6:02 PM on Tuesday, February 9th, 2021

To say that PyroGenesis Canada (PYR:TSX) and its CEO, Peter Pascali, share a mutual love and respect with shareholders unlike anything we have ever seen is not an overstatement.  

This is a group (Company, CEO and Shareholders) that have been through the highs and lows of PyroGenesis over the years TOGETHER.  That bond only got tighter when Pascali took to the PYR Verified Forum on AGORACOM to speak with investors directly and openly with his first ever post on June 21, 2017 followed by more than 20 in-depth videos in which he took his engagement with investors even deeper by answering every single question possible to the best of his ability.  

Knowing this, it should not surprise anybody learning about PyroGenesis for the first time that shareholders have coined the rallying call of “In Peter We Trust”.  

Today PyroGenesis, Pascali and shareholders shared another major milestone together in a live Q&A that coincided with PyroGenesis surpassing a $1 BILLION MARKET CAP.  It was an incredibly special event that could not be made clearer than by many of the questions and comments that referred not just to the Company’s bottom – but to its soul and philosophy.    

I’ve never seen it before.  All I can say is that it is a thrill to be witness to and part of something this deeply special in an industry that rarely looks beyond the next quarter.  

Congratulations to Peter, the Pyro team and this incredible group of shareholders.  

George and the AGORACOM team.  

Watch, listen and enjoy today’s interview with CEO Peter Pascali.

Tags: , , , , ,
Posted in AGORACOM Via Satellite, Featured, PyroGenesis Canada Inc. | Comments Off on VIDEO – PyroGenesis $PYR.ca Goes Live For Q&A With Shareholders As Market Cap Surpasses $1 BILLION

« Older Entries
Newer Entries »